Outcomes in patients with MCL have improved with the development of Bruton's tyrosine kinase (BTK) inhibitors such as ibrutinib, but in patients with disease that has relapsed after receiving this therapy median OS ranges from 6 to 10 months [6]. The gene discussed is BTK; the disease is mantle cell lymphoma.